August 20, 2021 09:18 AM EDTUpdated 09:44 AM

Novavax grabs another CFO while Pat Cotroneo retires from FibroGen; Eli Lilly reassembles key staff after biomedicines unit split

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Paul Schloesser

Associate Editor

→ The perennial Charlie Brown of vaccine development, Novavax is grappling with Lucy’s knack for pulling the football away once again, this time with its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novavax grabs another CFO while Pat Cotroneo retires from FibroGen; Eli Lilly reassembles key staff after biomedicines unit split

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

No­vavax grabs an­oth­er CFO while Pat Cotro­neo re­tires from Fi­bro­Gen; Eli Lil­ly re­assem­bles key staff af­ter bio­med­i­cines unit split

Senior Editor

Editor

Associate Editor

Sign up to read this article for free.

Novavax grabs another CFO while Pat Cotroneo retires from FibroGen; Eli Lilly reassembles key staff after biomedicines unit split